Intervention not reported
Adverse effects Time of measurement: 1 to 48 hours after treatment, end of treatment Scale of measurement:not stated · people suffering from high altitude illness
1 finding from 1 review
Mortality, near term corrected age or discharge · preterm infants
Lower showed no clear difference in mortality, near term corrected age or discharge compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Neurodevelopmental disability · preterm infants
Lower showed no clear difference in neurodevelopmental disability compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Intubation in the delivery room · preterm infants
Lower showed no clear difference in intubation in the delivery room compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · preterm infants
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · preterm infants
Lower showed no clear difference in severe intraventricular haemorrhage (grade 3 or 4) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Necrotising enterocolitis · preterm infants
Lower showed no clear difference in necrotising enterocolitis compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Chronic lung disease · preterm infants
It is very uncertain whether lower changes chronic lung disease (36 weeks' corrected age) compared with higher oxygen concentrations titrated to target oxygen saturations… (very low certainty).
1 finding from 1 review
Risk of acute mountain sickness · participants at risk of high altitude illness
Sumatriptan may leads to lower risk of acute mountain sickness compared with placebo (low certainty).
1 finding from 1 review
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of acute mountain sickness · participants at risk of high altitude illness
Acetazolamide may leads to lower risk of acute mountain sickness compared with spironolactone (low certainty).
1 finding from 1 review
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of acute mountain sickness · participants at risk of high altitude illness
Magnesium citrate showed no clear difference in risk of acute mountain sickness compared with placebo (low certainty).
1 finding from 1 review
Risk of adverse events: Loose stools · participants at risk of high altitude illness
Magnesium citrate may leads to higher risk of adverse events: Loose stools compared with placebo (low certainty).
1 finding from 1 review
Risk of acute mountain sickness · participants at risk of high altitude illness
1 finding from 1 review
Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Acetazolamide probably leads to lower incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Dexamethasone showed no clear difference in incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: General‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
1 finding from 1 review
Adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review